Natera, Inc. (NASDAQ:NTRA) Shares Sold by Truist Financial Corp

Truist Financial Corp lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 13.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,666 shares of the medical research company’s stock after selling 6,517 shares during the quarter. Truist Financial Corp’s holdings in Natera were worth $6,596,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc boosted its position in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the period. Principal Securities Inc. boosted its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 59 shares during the period. Covestor Ltd raised its stake in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares in the last quarter. Finally, True Wealth Design LLC bought a new stake in Natera during the 3rd quarter valued at $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock opened at $162.31 on Friday. Natera, Inc. has a 1-year low of $69.74 and a 1-year high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $21.43 billion, a price-to-earnings ratio of -92.22 and a beta of 1.66. The stock’s fifty day simple moving average is $167.98 and its 200-day simple moving average is $145.54.

Insider Activity

In other news, Director Roelof Botha sold 87,473 shares of Natera stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the transaction, the director now owns 1,224,787 shares in the company, valued at approximately $207,135,977.44. The trade was a 6.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now owns 267,629 shares in the company, valued at $44,150,756.13. This represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 295,772 shares of company stock worth $49,741,699. 7.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have weighed in on the company. JPMorgan Chase & Co. lifted their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. TD Cowen lifted their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Sanford C. Bernstein lifted their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, Robert W. Baird lifted their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average price target of $170.94.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.